Considering the heterogeneous nature of HER2 + breast cancer and the complexity of the interplay between the tumor and the immune system, it is evident that more work is required to clarify the prognostic role of TILs in different HER2 + subtypes. The gene discussed is ERBB2; the disease is neoplasm.